<DOC>
	<DOC>NCT00846027</DOC>
	<brief_summary>This single-arm study assessed the efficacy and safety of first-line treatment with Avastin (bevacizumab) in combination with taxane-based chemotherapy (paclitaxel and gemcitabine) in patients with HER-2 negative breast cancer. Patients received Avastin 10 mg/kg iv, paclitaxel 150 mg/m^2 iv, and gemcitabine 200 mg/m^2 iv on Day 1 and Day 15 of each 4-week treatment cycle until disease progression, death, or withdrawal of consent.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Female patients, ≥ 18 years of age. Breast cancer, with measurable, locally recurrent or metastatic lesions, or patients with bone metastasis only. HER2 negative disease. Candidates for chemotherapy. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. Previous chemotherapy for metastatic or locally advanced breast cancer. Previous radiotherapy for treatment of metastatic breast cancer. Any prior adjuvant treatment with anthracyclines completed &lt; 6 months prior to enrollment. Chronic daily treatment with corticosteroids (≥ 10 mg/day), aspirin (&gt; 325 mg/day) or clopidogrel (&gt; 75mg/day).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>